Cancer Targets in the Ras Pathway

Cancer Research Institute, University of California San Francisco Comprehensive Cancer Center, 94115, USA.
Cold Spring Harbor Symposia on Quantitative Biology 02/2005; 70:461-7. DOI: 10.1101/sqb.2005.70.044
Source: PubMed


Ras proteins play a direct causal role in human cancer and in other diseases. Mutant H-Ras, N-Ras, and K-Ras occur in varying frequencies in different tumor types, for reasons that are not known. Other members of the Ras superfamily may also contribute to cancer. Mutations also occur in downstream pathways, notably B-Raf, PTEN, and PI 3' kinase: These pathways interact at multiple points, including cyclin D1, and act synergistically. In some cases mutations in Ras and effectors are mutually exclusive; in other cases, they coexist. Drugs blocking elements of the pathway are in different stages of clinical development. One of these, the Raf kinase/VEGF-R2 inhibitor Sorafenib, has already been approved for treatment of renal cancer and is being tested in other indications. However, therapeutic targets in the Ras pathway have not yet been fully validated as bona fide targets.

Download full-text


Available from: Osamu Tetsu, Mar 16, 2015
Show more